临床研究：

  牵头开展全国多中心III期临床研究3项以及多项II期前瞻性研究，内容涉及直肠癌术后同步放化疗方案研究、优化局部晚期直肠癌术前治疗模式和局部晚期胃癌D2手术后放化疗的随机对照研究。三项III期研究内容为目前直肠癌和胃癌综合治疗的研究热点，其中直肠癌术后同步放化疗方案的前瞻性、随机对照III期研究，确定了单药氟尿嘧啶类药物同步放化疗与双药同步放化疗疗效类似，该研究结果进一步为直肠癌术后同步放化疗提供了新的循证医学证据，初步结果被美国NCCN指南引用；优化局部晚期直肠癌术前治疗模式是一项全国多中心研究，参与的全国中心达14家，其结果将填补该领域的空白；胃癌D2术后研究结果将成为中国自主研发的数据。3项III期研究预计分别纳入500-600例以上病例，最终结果将在各自专业领域提供循证医学证据。

指南制定：

  牵头组织国内直肠癌放疗、外科、影像、内科专家，借鉴直肠癌放疗靶区勾画的国际指南，广泛收集数据并结合我国大型肿瘤中心的经验，制定并发表了中国首部“直肠癌术前／术后适形调强放疗靶区勾画共识与图谱”，减少不同单位或不同医生之间靶区勾画的差异，为我国直肠癌放疗规范化、标准化奠定了坚实基础。

学术推广：

  2015年始，先后牵头成立了中国医师协会结直肠肿瘤放疗专委会、抗癌协会放疗专委会直肠癌学组和北京医学会放疗分会胃肠学组三大学术交流平台，分别担任主任委员和组长。集合全国消化道肿瘤放疗专家，会同其他学科专家，在各地开展形式多样、内容丰富的多学科会诊活动及规范化诊疗巡讲。截止2019年6月底，已组织学术活动近40次，足迹遍及国内20余个省区，极大提高了消化道肿瘤放疗技术和理念在全国的普及，一定程度上改善了地区间放疗水平发展不平衡、综合治疗理念单薄的现状。

目前在研课题：

1.国家自然科学基金面上项目：LncRNA-RP11-474D1调控局部晚期直肠癌放疗敏感性的功能及机制研究

2.首都卫生发展专项基金重点攻关课题：基于危险度分层的直肠癌新辅助放化疗前瞻性、多中心、随机对照研究

3.“北京希望马拉松”专项基金课题：结直肠癌筛查和干预新技术新方案的研究

4.肿瘤医学协同创新项目：优化局部晚期、中低位直肠癌术前放、化疗模式的前瞻性Ⅱ、Ⅲ期研究

5.协和院所课题：局部晚期胃癌全新辅助治疗的II期研究

会议获奖情况：

1.2019年第61届ASTRO Bestof ASTRO 汇报人：刘文扬，责任作者：金晶 获奖题目：ImprovedPrediction of EarlyMetastases by Baseline Circulating Tumor Cell Counts forLocally AdvancedRectal Cancer in Neoadjuvant Setting: Exploratory Analysis froma Phase III Trial

2.2019年CSTRO 优秀论文奖口头发言 汇报人：唐源，责任作者：金晶 题目：局部晚期中低位直肠癌术前短程放疗联合新辅助化疗对比同步放化疗的II/III期研究(STELLAR)单中心经验

3.2019年CSTRO 优秀论文奖口头发言 汇报人：李宁，责任作者：金晶 获奖题目：基于弥散加权成像深度学习的影像组学提高预测直肠癌新辅助同步放化疗反应准确性的研究

4.2018年60届ASTRO Best of ASTRO 汇报人：王鑫，责任作者：金晶 获奖题目：ARandomized Phase II Trial ofNeoadjuvant Chemotherapy Compared withChemoradiotherapy in Locally AdvancedGastric Adenocarcinoma

5.2018年CSTRO 优秀论文奖口头发言 汇报人：唐源，责任作者：金晶 题目：优化局部晚期、中低位直肠癌术前放、化疗模式的前瞻性III期研究-中期分析

6.2018年第八届济南放射肿瘤学青年论坛 优秀论文奖 口头发言 汇报人：唐源，责任作者：金晶题目：优化局部晚期、中低位直肠癌术前放、化疗模式的前瞻性III期研究-中期分析

7.2017年CSTRO 优秀论文奖口头发言 汇报人：李帅，责任作者：金晶 题目：降期及新辅助治疗评分(NAR)对接受术前同步放化疗联合根治性手术II/III期中低位直肠癌预后影响分析

8.2017年CSTRO 优秀论文奖口头发言 汇报人：唐源，责任作者：金晶 题目：局部晚期中低位直肠癌术前短程放疗联合新辅助化疗对比同步放化疗的II/III期研究(STELLAR)更新结果

9.2016年第58届ASTRO Best of ASTRO 汇报人：唐源，责任作者：金晶 获奖题目：Theinitial results for a phase III study ofshort-term versus long-termchemoradiotherapy in locally advanced rectal cancer(STELLAR trial)

10.2016年58届ASTRO Best ofASTRO 汇报人：王鑫，责任作者：金晶 获奖题目：Arandomized phase II trial of neoadjuvant chemotherapycompared withchemoradiotherapy in locally advanced gastroesophageal andgastricadenocarcinoma: preliminary results

近5年第一作者、责任作者英文文章：      

1. Liu WY, Jing J✳, Tang Y, Li N, Tang Y, Wang J, Cheng YJ, Yang L, Fang H, Lu NN, Qi SN, Chen B, Wang SL, Song YW, Liu YP, Li YX, Liu Z, Zhou HT, Liang JW, Pei W, Wang XS, Zhang HZ, Zhou ZX.Safety and efficacy of preoperative chemoradiotherapy in fit older patients with intermediate or locally advanced rectal cancer evaluated by comprehensive geriatric assessment: A planned interim analysis of a multicenter, phase II trial. J Geriatr Oncol, 2020.doi.10.1016/j.jgo.2020.10.016  IF: 2.8

2. Jie Yang, Ying Huang, Yanru Feng, Hongmin Li, Ting Feng, Jinna Chen, Luxi Yin, Weihu Wang, Shulian Wang, Yueping Liu, Yongwen Song, Yexiong Li, Jing Jin✳, Wen Tan✳, Dongxin Lin. Associations of genetic variations in mismatch repair genes MSH3 and PMS1 with acute adverse events and survival in patients with rectal cancer receiving postoperative chemoradiotherapy. Cancer Research and Treatment. 2019; 51(3): 1198-1206. doi: 10.4143/crt.2018.527 IF: 3.772

3. Yu J, Li N, Tang Y, Wang X, Tang Y, Wang SL, Song YW, Liu YP, Li YX, Jin J✳: Outcomes after hypofractionated stereotactic radiotherapy for colorectal cancer oligometastases.Journal of surgical oncology 2019, 119(4):532-538. doi:10.1002/jso.25361 IF:3.11

4. Wang J, Zhao H, Yu J, Xu X, Liu W, Jing H, Li N, Tang Y, Li Y, Cai J, Jin J✳: MiR-92b targets p57kip2 to modulate the resistance of hepatocellular carcinoma (HCC) to ionizing radiation (IR) -based radiotherapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019, 110:646-655. doi: 10.1016/j.biopha.2018.11.080 IF:3.74

5. Li N, Yu J, Luo A, Tang Y, Liu W, Wang S, Liu Y, Song Y, Fang H, Chen B, Qi S, Lu N, Yu Z, Li Y, Liu Z, Jin J✳: LncRNA and mRNA signatures associated with neoadjuvant chemoradiotherapy downstaging effects in rectal cancer.J Cell Biochem 2019, 120(4):5207-5217.doi: 10.1002/jcb.27796 IF:2.96

6. Li N, Wang X, Tang Y, Zhao D, Chi Y, Yang L, Jiang L, Jiang J, Liu W, Tang Y, Fang H, Liu Y, Song Y, Wang S, Jin J✳, Li Y: A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer. BMC cancer 2018, 18(1):803.doi:10.1186/s12885-018-4707-9 IF:3.29

7. Wang X, Zhao DB, Yang L, Chi Y, Tang Y, Li N, Wang SL, Song YW, Liu YP, Liu WY, Ren H, Zhang T, Wang JY, Chen XS, Fang H, Wang WH, Li YX, Jin J✳: S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study. Br J Cancer 2018, 118(3):338-343.doi:10.1038/bjc.2017.424 IF:6.18

8. Li N, Jin J✳, Yu J, Li S, Tang Y, Ren H, Liu W, Wang S, Liu Y, Song Y, Fang H, Yu Z, Li Y: Down-staging depth score to predict outcomes in locally advanced rectal cancer achieving ypI stage after neoadjuvant chemo-radiotherapy versus denovo stage pI cohort: A propensity score-matched analysis. Chinese journal of cancer research 2018, 30(3):373-381. doi:10.21147/j.issn.1000-9604.2018.03.09 IF:3.69

9. Huang Y, Feng Y, Ren H, Zhang M, Li H, Qiao Y, Feng T, Yang J, Wang W, Wang S, Liu Y, Song Y, Li Y, Jin J✳, Tan W, Lin D: Associations of Genetic Variations in MicroRNA Seed Regions With Acute Adverse Events and Survival in Patients With Rectal Cancer Receiving Postoperative Chemoradiation Therapy. International journal of radiation oncology, biology, physics 2018, 100(4):1026-1033. doi:10.1016/j.ijrobp.2017.12.256 IF:5.13

10. Wang X, Tian Y, Tang Y, Hu ZH, Zhang JJ, Fu GS, Ma P, Ren H, Zhang T, Li N, Liu WY, Fang H, Li YX, Jin J✳: Tomotherapy as an adjuvant treatment for gastroesophageal junction and stomach cancer may reduce bowel and bone marrow toxicity compared to intensity-modulated radiotherapy and volumetric-modulated arc therapy. Oncotarget 2017,8 (24) :39727-39735.doi:10.18632/oncotarget.14459 IF:5.17

11. Feng YR, Jin J✳, Ren H, Wang X, Wang SL, Wang WH, Song YW, Liu YP, Tang Y, Li N, Liu XF, Fang H, Yu ZH, Li YX: Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate. BMC cancer 2017, 17(1):182.doi:10.1186/s12885-017-3170-3 IF:3.19

12. Yu J, Li N, Wang X, Ren H, Wang W, Wang S, Song Y, Liu Y, Li Y, Zhou X, Luo A, Liu Z, Jin J✳: Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. Oncotarget 2016, 7(39):64233-64243. doi:10.18632/oncotarget.11649 IF:5.17

13. Wang X, Jin J✳, Yang Y, Liu WY, Ren H, Feng YR, Xiao Q, Li N, Deng L, Fang H, Jing H, Lu NN, Tang Y, Wang JY, Wang SL, Wang WH, Song YW, Liu YP, Li YX: Adjuvant treatment may benefit patients with high-risk upper rectal cancer: A nomogram and recursive partitioning analysis of 547 patients. Oncotarget 2016, 7(40):66160-66169. doi:10.18632/oncotarget.10718 IF:5.17

14. Li N, Dou L, Zhang Y, Jin J✳, Wang G, Xiao Q, Li Y, Wang X, Ren H, Fang H, Wang W, Wang S, Liu Y, Song Y. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer. Gastrointestinal Endoscopy 2017, 85(3):669-674. doi: 10.1016/j.gie.2016.06.042 IF:6.5

15. Liu WY, Dinapoli N, Wang X, Meldolesi E, Gambacorta MA, Chiloiro G, Ren H, Fang H, Lu NN, Tang Y, Deng L, Wang JY, Jing H, Xiao Q, Feng YR, Li YX, Wang SL, Song YW, Liu YP, Wang WH, Valentini V, Jin J✳. Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model. Oncotarget 2016, 7(29):46536-46544.doi:10.18632/oncotarget.10228 IF:5.17

16. Tang Y, Liu WY, Jin J✳, Zhang HZ, Yang L, Ren H, Fang H, Wang WH, Song YW, Liu YP, Wang SL, Li YX. Preoperative chemoradiation with capecitabine for rectal cancer in elderly patients: a phase I trial. Int J Colorectal Dis. 2016,31(8):1547-9 .doi:10.1007/s00384-016-2577-7 IF:2.53

17. Jianyang W, Yuan T, Yuan T, Xin W, Ning L, Hua R, Hui F, Yanru F, Shulian W, Yongwen S, Yueping L, Weihu W, Yexiong L, Jing J✳. A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer. Radiol Med 2016,121(4):308-14. doi：10.1007/s11547-015-0605-2 IF:1.82

18. Wang J, Tian Y, Tang Y, Wang X, Li N, Ren H, Fang H, Feng Y, Wang S, Song Y, Liu Y, Wang W, Li Y, Jin J✳: A Phase II prospective nonrandomized trial of magnetic resonance imaging-guided hematopoietic bone marrow-sparing radiotherapy for gastric cancer patients with concurrent chemotherapy. OncoTargets and therapy 2016, 1(9):2701-2707. doi:10.2147/OTT.S91586 IF:2.66

19. Feng YR, Zhu Y, Liu LY, Wang WH, Wang SL, Song YW, Wang X, Tang Y, Liu YP, Ren H, Fang H, Zhang SP, Liu XF, Yu ZH, Li YX, Jin J✳:Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.2. Oncotarget 2016,7(18):25576-84. doi:10.18632/oncotarget.8226 IF:5.17